1. Park JJ, Lee CJ, Park SJ, et al. Heart failure statistics in Korea, 2020: a report from the Korean Society of Heart Failure. Int J Heart Fail 2021;3:224–236.

2. Marwick TH. Methods used for the assessment of LV systolic function: common currency or tower of Babel? Heart 2013;99:1078–1086.

3. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726.

4. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297–3317.

5. Kim MN, Park SM. Heart failure with preserved ejection fraction: insights from recent clinical researches. Korean J Intern Med 2020;35:514–534.

6. Smiseth OA, Morris DA, Cardim N, et al. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2022;23:e34.

7. Kim MN, Park SM, Kim HD, et al. Assessment of the left ventricular diastolic function and its association with the left atrial pressure in patients with atrial fibrillation. Int J Heart Fail 2020;2:55–65.

8. Jørgensen TH, Søndergaard L. transcatheter implantation of interatrial shunt devices to lower left atrial pressure in heart failure. Int J Heart Fail 2022;4:12–23.

9. Kim HD, Cho DH, Kim MN, et al. Left atrial dysfunction, fibrosis and the risk of thromboembolism in patients with paroxysmal and persistent atrial fibrillation. Int J Heart Fail 2022;4:42–53.

10. Voigt JU, Pedrizzetti G, Lysyansky P, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr 2015;28:183–193.

11. Sarvari SI, Gjesdal O, Gude E, et al. Early postoperative left ventricular function by echocardiographic strain is a predictor of 1-year mortality in heart transplant recipients. J Am Soc Echocardiogr 2012;25:1007–1014.

12. Kim SA, Park SM, Kim MN, Shim WJ. Assessment of left ventricular function by layer-specific strain and its relationship to structural remodelling in patients with hypertension. Can J Cardiol 2016;32:211–216.

13. Zhang KW, French B, May Khan A, et al. Strain improves risk prediction beyond ejection fraction in chronic systolic heart failure. J Am Heart Assoc 2014;3:e000550.

14. Yingchoncharoen T, Agarwal S, Popović ZB, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr 2013;26:185–191.

15. Santoro C, Arpino G, Esposito R, et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging 2017;18:930–936.

16. Kim MN, Kim SR, Kim HD, et al. Serial changes of layer-specific myocardial function according to chemotherapy regimen in patients with breast cancer. Eur Heart J Open 2022;2:oeac008.

17. Lyon AR, López-Fernández T, Couch LS, et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229–4361.

18. Thavendiranathan P, Negishi T, Somerset E, et al.; SUCCOUR Investigators. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol 2021;77:392–401.

19. Negishi T, Thavendiranathan P, Penicka M, et al. Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 3-year results of the SUCCOUR trial. JACC Cardiovasc Imaging 2023;16:269–278.

20. Harjola VP, Mebazaa A, Čelutkienė J, et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail 2016;18:226–241.

21. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685–713quiz 786-788.

22. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Basis for detection of stenosis using venous administration of microbubbles during myocardial contrast echocardiography: bolus or continuous infusion? J Am Coll Cardiol 1998;32:252–260.

23. Cardim N, Galderisi M, Edvardsen T, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging 2015;16:280.

24. Pellikka PA, Arruda-Olson A, Chaudhry FA, et al. Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: from the American Society of Echocardiography. J Am Soc Echocardiogr 2020;33:1–41.e8.

25. Vahanian A, Beyersdorf F, Praz F, et al.; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561–632.

26. Ha JW, Andersen OS, Smiseth OA. Diastolic stress test: invasive and noninvasive testing. JACC Cardiovasc Imaging 2020;13(1 Pt 2):272–282.

27. Baumgartner H, Hung J, Bermejo J, et al.; European Association of Echocardiography. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009;22:1–23quiz 101-102.

28. Shah SJ, Lam CSP, Svedlund S, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 2018;39:3439–3450.

29. Taqueti VR, Solomon SD, Shah AM, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 2018;39:840–849.

30. Kim SR, Cho DH, Kim MN, Park SM. Rationale and study design of differences in cardiopulmonary exercise capacity according to coronary microvascular dysfunction and body composition in patients with suspected heart failure with preserved ejection fraction. Int J Heart Fail 2021;3:237–243.

31. Orde S, Slama M, Hilton A, Yastrebov K, McLean A. Pearls and pitfalls in comprehensive critical care echocardiography. Crit Care 2017;21:279.

32. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017;43:304–377.

33. Lee JH, Uhm JS, Shin DG, et al. Clinical significance of changes in the corrected QT interval in stress-induced cardiomyopathy. Korean J Intern Med 2016;31:507–516.

34. McLean AS. Echocardiography in shock management. Crit Care 2016;20:275.

35. Medina de Chazal H, Del Buono MG, et al. Stress cardiomyopathy diagnosis and treatment: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:1955–1971.

36. Douflé G, Roscoe A, Billia F, Fan E. Echocardiography for adult patients supported with extracorporeal membrane oxygenation. Crit Care 2015;19:326.

37. Lee TH, Hamilton MA, Stevenson LW, et al. Impact of left ventricular cavity size on survival in advanced heart failure. Am J Cardiol 1993;72:672–676.

38. Park SM, Kim YH, Ahn CM, Hong SJ, Lim DS, Shim WJ. Relationship between ultrasonic tissue characterization and myocardial deformation for prediction of left ventricular reverse remodelling in non-ischaemic dilated cardiomyopathy. Eur J Echocardiogr 2011;12:887–894.

39. Rickenbacher PR, Trindade PT, Haywood GA, et al. Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristics and survival. J Am Coll Cardiol 1996;27:1192–1197.

40. Kim MN, Park SM. Current status of pharmacologic and non-pharmacologic therapy in heart failure with preserved ejection fraction. Heart Fail Clin 2021;17:463–482.

41. Morris DA, Belyavskiy E, Aravind-Kumar R, et al. Potential usefulness and clinical relevance of adding left atrial strain to left atrial volume index in the detection of left ventricular diastolic dysfunction. JACC Cardiovasc Imaging 2018;11:1405–1415.

42. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013;34:2281–2329.

43. Su MY, Lin LY, Tseng YH, et al. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging 2014;7:991–997.

44. Webb J, Fovargue L, Tøndel K, et al. The emerging role of cardiac magnetic resonance imaging in the evaluation of patients with HFpEF. Curr Heart Fail Rep 2018;15:1–9.

45. Casolo G, Minneci S, Manta R, et al. Identification of the ischemic etiology of heart failure by cardiovascular magnetic resonance imaging: diagnostic accuracy of late gadolinium enhancement. Am Heart J 2006;151:101–108.

46. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445–1453.

47. Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 2003;108:1945–1953.

48. Tarantini G, Razzolini R, Cacciavillani L, et al. Influence of transmurality, infarct size, and severe microvascular obstruction on left ventricular remodeling and function after primary coronary angioplasty. Am J Cardiol 2006;98:1033–1040.

49. Baks T, van Geuns RJ, Biagini E, et al. Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics. J Am Coll Cardiol 2006;47:40–44.

50. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020;142:e533.

51. Habib G, Bucciarelli-Ducci C, Caforio ALP, EACVI Scientific Documents Committee, et al; Indian Academy of Echocardiography. Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document In collaboration with the “Working Group on myocardial and pericardial diseases” of the European Society of Cardiology Endorsed by The Indian Academy of Echocardiography. Eur Heart J Cardiovasc Imaging 2017;18:1090–1121.

52. Klem I, Klein M, Khan M, et al. Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy. Circulation 2021;143:1343–1358.

53. Baggiano A, Boldrini M, Martinez-Naharro A, et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2020;13(1 Pt 1):69–80.

54. Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging 2021;14:189–199.

55. Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging 2019;12:810–819.

56. Terasaki F, Azuma A, Anzai T, et al.; Japanese Circulation Society Joint Working Group. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis - digest version. Circ J 2019;83:2329–2388.

57. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 2018;72:3158–3176.

58. Adler Y, Charron P, Imazio M, et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015;36:2921–2964.

59. Knuuti J, Wijns W, Saraste A, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407–477.

60. le Polain de Waroux JB, Pouleur AC, Goffinet C, Pasquet A, Vanoverschelde JL, Gerber BL. Combined coronary and late-enhanced multidetector-computed tomography for delineation of the etiology of left ventricular dysfunction: comparison with coronary angiography and contrast-enhanced cardiac magnetic resonance imaging. Eur Heart J 2008;29:2544–2551.

61. Behar JM, Rajani R, Pourmorteza A, et al. Comprehensive use of cardiac computed tomography to guide left ventricular lead placement in cardiac resynchronization therapy. Heart Rhythm 2017;14:1364–1372.

62. Driessen RS, van Diemen PA, Raijmakers PG, et al. Functional stress imaging to predict abnormal coronary fractional flow reserve: the PACIFIC 2 study. Eur Heart J 2022;43:3118–3128.

63. Saraste A, Knuuti J, Bengel F. Phenotyping heart failure by nuclear imaging of myocardial perfusion, metabolism, and molecular targets. Eur Heart J Cardiovasc Imaging 2023 Jun 9 [Epub]. DOI: 10.1093/ehjci/jead128.

64. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002;39:1151–1158.

65. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319–328.

66. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585–2594.

67. Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail 2019;7:709–716.

68. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538–1543.